Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Labeling Toll-Free AER Number Provision Included In House Bill

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine alkaloid-containing dietary supplements would be prohibited from sale to people under 18 and limited to "behind-the-counter" distribution under a bill introduced by freshman Rep. Susan Davis (D-Calif.) Oct. 9.

You may also be interested in...



Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel